{"id":"https://openalex.org/W150400455","doi":"https://doi.org/10.1182/blood.v122.21.665.665","title":"Phase I Study Of LY2784544, a JAK2 Selective Inhibitor, In Patients With Myelofibrosis (MF), Polycythemia Vera (PV), and Essential Thrombocythemia (ET)","display_name":"Phase I Study Of LY2784544, a JAK2 Selective Inhibitor, In Patients With Myelofibrosis (MF), Polycythemia Vera (PV), and Essential Thrombocythemia (ET)","publication_year":2013,"publication_date":"2013-11-15","ids":{"openalex":"https://openalex.org/W150400455","doi":"https://doi.org/10.1182/blood.v122.21.665.665","mag":"150400455"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v122.21.665.665","doi":"https://doi.org/10.1182/blood.v122.21.665.665","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v122.21.665.665","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5085521139","display_name":"Sr\u0111an Verstov\u0161ek","orcid":"https://orcid.org/0000-0002-6912-8569","observed_orcids":["https://orcid.org/0000-0002-6912-8569"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Srdan Verstovsek","raw_affiliation_strings":["Department of Leukemia, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA,","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039057642","display_name":"Ruben A. Mesa","orcid":"https://orcid.org/0000-0001-5880-7972","observed_orcids":["https://orcid.org/0000-0001-5880-7972"]},"institutions":[{"id":"https://openalex.org/I4210125099","display_name":"Mayo Clinic in Arizona","ror":"https://ror.org/03jp40720","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723","https://openalex.org/I4210125099"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ruben A Mesa","raw_affiliation_strings":["Hematology/Oncology, Mayo Clinic, Scottsdale, AZ, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology/Oncology, Mayo Clinic, Scottsdale, AZ, USA,","institution_ids":["https://openalex.org/I4210125099"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034181399","display_name":"Mohamed E. Salama","orcid":"https://orcid.org/0000-0001-6696-0061","observed_orcids":["https://orcid.org/0000-0001-6696-0061"]},"institutions":[{"id":"https://openalex.org/I223532165","display_name":"University of Utah","ror":"https://ror.org/03r0ha626","country_code":"US","type":"education","lineage":["https://openalex.org/I223532165"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mohamed E Salama","raw_affiliation_strings":["Department of Pathology, University of Utah, Salt Lake City, UT, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pathology, University of Utah, Salt Lake City, UT, USA,","institution_ids":["https://openalex.org/I223532165"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004676919","display_name":"Jennifer L K Giles","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Jennifer L K Giles","raw_affiliation_strings":["Lilly Oncology, Eli Lilly and Co, Indianapolis, IN, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Oncology, Eli Lilly and Co, Indianapolis, IN, USA,","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034695625","display_name":"Celine Pitou","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Celine Pitou","raw_affiliation_strings":["Lilly Oncology, Eli Lilly and Co, Indianapolis, IN, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Oncology, Eli Lilly and Co, Indianapolis, IN, USA,","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113726350","display_name":"Annamaria Hayden Zimmermann","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Annamaria Hayden Zimmermann","raw_affiliation_strings":["Lilly Oncology, Eli Lilly and Co, Indianapolis, IN, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Oncology, Eli Lilly and Co, Indianapolis, IN, USA,","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004140914","display_name":"Gregory L. Price","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Gregory L Price","raw_affiliation_strings":["Lilly Oncology, Eli Lilly and Co, Indianapolis, IN, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Oncology, Eli Lilly and Co, Indianapolis, IN, USA,","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009773917","display_name":"Richard A. Walgren","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Richard A Walgreen","raw_affiliation_strings":["Lilly Oncology, Eli Lilly and Co, Indianapolis, IN, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Oncology, Eli Lilly and Co, Indianapolis, IN, USA,","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5042381475","display_name":"Josef T. Prchal","orcid":"https://orcid.org/0000-0002-8019-2940","observed_orcids":["https://orcid.org/0000-0002-8019-2940"]},"institutions":[{"id":"https://openalex.org/I223532165","display_name":"University of Utah","ror":"https://ror.org/03r0ha626","country_code":"US","type":"education","lineage":["https://openalex.org/I223532165"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Josef Prchal","raw_affiliation_strings":["Hematology Division, University of Utah, Salt Lake City, UT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology Division, University of Utah, Salt Lake City, UT, USA","institution_ids":["https://openalex.org/I223532165"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5004140914","https://openalex.org/A5004676919","https://openalex.org/A5009773917","https://openalex.org/A5034695625","https://openalex.org/A5113726350"],"corresponding_institution_ids":["https://openalex.org/I168537998"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":3.1186,"has_fulltext":false,"cited_by_count":24,"citation_normalized_percentile":{"value":0.92135332,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"122","issue":"21","first_page":"665","last_page":"665"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10746","display_name":"Platelet Disorders and Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/jak2-inhibitors","display_name":"JAK2 inhibitors","score":0.8840000033378601},{"id":"https://openalex.org/keywords/myelofibrosis","display_name":"myelofibrosis","score":0.8949999809265137},{"id":"https://openalex.org/keywords/polycythemia-vera","display_name":"polycythemia vera","score":0.9990000128746033},{"id":"https://openalex.org/keywords/essential-thrombocythemia","display_name":"essential thrombocythemia","score":1.0},{"id":"https://openalex.org/keywords/jak2-v617f-mutation","display_name":"JAK2 V617F mutation","score":0.972000002861023},{"id":"https://openalex.org/keywords/myeloproliferative-neoplasms","display_name":"myeloproliferative neoplasms","score":0.9240000247955322},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.7829999923706055},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8330000042915344},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8569999933242798},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.7519999742507935}],"concepts":[{"id":"https://openalex.org/C2778837598","wikidata":"https://www.wikidata.org/wiki/Q948318","display_name":"Polycythemia vera","level":2,"score":0.8226208686828613},{"id":"https://openalex.org/C2780076729","wikidata":"https://www.wikidata.org/wiki/Q1752571","display_name":"Myelofibrosis","level":3,"score":0.8131701946258545},{"id":"https://openalex.org/C2781057849","wikidata":"https://www.wikidata.org/wiki/Q1368780","display_name":"Essential thrombocythemia","level":3,"score":0.8091001510620117},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.745215892791748},{"id":"https://openalex.org/C2776112149","wikidata":"https://www.wikidata.org/wiki/Q7383611","display_name":"Ruxolitinib","level":4,"score":0.7383205890655518},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5561601519584656},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.5504617691040039},{"id":"https://openalex.org/C2781107747","wikidata":"https://www.wikidata.org/wiki/Q1898104","display_name":"Myeloproliferative neoplasm","level":4,"score":0.4705184996128082},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.42056915163993835},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.41984444856643677},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.374717652797699},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.22730398178100586},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.2147502601146698}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v122.21.665.665","doi":"https://doi.org/10.1182/blood.v122.21.665.665","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v122.21.665.665","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2554340669","https://openalex.org/W2561728622","https://openalex.org/W2584660382","https://openalex.org/W2559563976","https://openalex.org/W4417007058","https://openalex.org/W2588005189","https://openalex.org/W2751027104","https://openalex.org/W2536171864","https://openalex.org/W2562725367","https://openalex.org/W2036153681"],"abstract_inverted_index":{"Abstract":[0],"Background":[1],"MF,":[2,94,150],"PV,":[3,95],"and":[4,14,96,111,131,135,160,177,181,211,254,260,264,275,387,414,425,458,480,504,638,656,662,687,693,698,704,709,714,719],"ET":[5,97,178,262],"are":[6,19],"neoplasms":[7],"characterized":[8],"by":[9,49],"activation":[10],"of":[11,17,24,40,57,73,118,133,158,162,277,296,323,358,365,519,542,548,559,575,605,625,648],"JAK2":[12,26,32,52,59,74,81,148],"signaling,":[13],"the":[15,22,129,165,185,206,286,319,336,339,356,463,587,590,614],"majority":[16,357],"cases":[18,48],"associated":[20,302,639],"with":[21,147,303,443,640],"gain":[23],"function":[25],"V617F":[27,53],"mutation.":[28],"Given":[29],"that":[30],"wild-type":[31,58],"plays":[33],"a":[34,70,89,137,200,370,517,530,537,579,596,601],"pivotal":[35],"role":[36],"in":[37,60,88,93,145,308,314,331,341,355,546,582,650],"multiple":[38,219],"stages":[39],"hematopoiesis":[41],"it":[42],"is":[43,69],"desirable":[44],"to":[45,63,127,204,214,228,230,291,345,376,449,568],"treat":[46],"JAK2V617F-positive":[47],"selectively":[50],"inhibiting":[51],"while":[54],"minimizing":[55],"inhibition":[56],"order":[61],"not":[62,238],"impede":[64],"normal":[65],"marrow":[66,608],"function.":[67],"LY2784544":[68,84,134,366,626,649],"selective":[71],"inhibitor":[72],"which":[75],"demonstrates":[76],"dose":[77,141,209,283,350,364,423,535,621,633],"dependent":[78],"selectivity":[79],"for":[80,142,175,271,622],"V617F/STAT5":[82],"signaling.":[83],"entered":[85],"clinical":[86,223,531,641],"testing":[87,647],"Phase":[90,645],"I":[91],"trial":[92],"patients":[98,146,233,245,427,438,522,551,576],"(I3X-MC-JHTA,":[99],"NCT01134120).":[100],"We":[101],"have":[102],"previously":[103],"reported":[104,466,578],"early":[105],"interim":[106],"analysis":[107],"from":[108,289,566,600],"this":[109],"study":[110,119,144,332,420,433,450],"provide":[112],"here":[113],"an":[114,329],"update":[115],"following":[116],"completion":[117],"enrollment.":[120],"Methods":[121],"The":[122,242,360,556],"study\u2019s":[123],"primary":[124],"objectives":[125,155],"were":[126,234,281,301,436,447,472,510],"determine":[128],"safety":[130],"tolerability":[132,276],"define":[136,205],"recommended":[138,618],"oral":[139],"daily":[140,363,372,623],"further":[143],"V617F-positive":[149],"ET,":[151],"or":[152,299,327,352],"PV.":[153],"Secondary":[154],"included":[156,199,246,389],"determination":[157],"pharmacokinetics":[159],"evaluation":[161],"response":[163,167,173],"using":[164,184],"IWG-MRT":[166],"criteria":[168,174],"(2006),":[169],"European":[170],"Leukemia":[171],"Net":[172],"PV":[176,592],"(EULN":[179],"2009),":[180],"symptom":[182],"burden":[183],"Myeloproliferative":[186],"Neoplasm":[187],"Symptom":[188,584],"Assessment":[189],"Form":[190],"(MPN-SAF)":[191],"(Scherber":[192],"et.":[193],"al.":[194],"Blood":[195],"2011).":[196],"Study":[197],"design":[198],"standard":[201],"3+3":[202],"dose-escalation":[203],"maximum":[207,361],"tolerated":[208,362,637],"(MTD)":[210],"was":[212,374,494,544,562,627],"amended":[213],"allow":[215],"cohort":[216,518],"expansions":[217],"at":[218,440,490,553,613],"doses":[220,295],"demonstrating":[221],"potential":[222],"merit.":[224],"Results":[225],"Patients":[226],"Prior":[227],"closing":[229],"enrollment,":[231],"47":[232],"consented;":[235],"9":[236],"did":[237],"meet":[239],"eligibility":[240],"screening.":[241],"38":[243],"treated":[244],"31":[247],"MF":[248,253,521],"(22":[249],"pMF,":[250],"6":[251,258,591],"post-PV":[252],"3":[255,306,497,499,501,507,528,594],"post-ET":[256],"MF),":[257],"PVs,":[259],"1":[261,400,407,495],"patient(s),":[263],"86%":[265],"had":[266],"received":[267,428,525],"prior":[268],"systemic":[269],"therapy":[270],"their":[272,432],"MPN.":[273],"Dosing":[274],"LY2784544:":[278],"Systemic":[279],"exposures":[280],"approximately":[282],"proportional":[284],"across":[285,384,469,534],"tested":[287],"range":[288],"30":[290],"300":[292],"mg.":[293,631],"Daily":[294],"200":[297],"mg":[298,379,430,442],"greater":[300],"CTCAE":[304],"Grade":[305,496,500,506,512],"increases":[307,313],"serum":[309,315,342],"creatinine.":[310],"In":[311],"general,":[312],"creatinine":[316,343,478],"occurred":[317],"within":[318],"first":[320],"2":[321,505],"weeks":[322,564],"either":[324],"starting":[325],"treatment":[326,452],"after":[328,349],"increase":[330],"drug":[333,353,451],"dose.":[334],"With":[335],"available":[337],"data,":[338],"elevations":[340],"appear":[344],"be":[346,377,611],"fully":[347],"reversible":[348],"reduction":[351,541],"holiday":[354],"patients.":[359],"when":[367],"given":[368],"on":[369,586],"continuous":[371],"basis":[373],"determined":[375],"120":[378,429,441,461,491,526,630],"per":[380],"day.":[381],"Serious":[382],"AEs,":[383],"all":[385,446,470],"grades":[386,471],"doses,":[388],"increased":[390,477,502],"creatinine/acute":[391],"renal":[392],"insufficiency":[393],"(4":[394],"grade":[395,398,401,405,408,412,417],"3,":[396],"5":[397],"2,":[399],"1),":[402,409,413],"hyperuricemia":[403],"(2":[404],"4,":[406],"hyperkalemia":[410],"(1":[411,416],"anemia":[415],"3).":[418],"This":[419,632],"allowed":[421],"intrapatient":[422],"escalation,":[424],"34":[426],"during":[431],"participation.":[434],"There":[435,509],"4":[437,513],"dosed":[439],"SAEs":[444],"but":[445],"unrelated":[448],"(anemia,":[453],"influenza,":[454],"enterococcal":[455],"bacteremia,":[456],"hematuria":[457],"pneumonia).":[459],"At":[460,571],"mg,":[462,492,527],"most":[464],"frequently":[465],"drug-related":[467],"AEs":[468,489],"diarrhea":[473],"(44%),":[474],"nausea":[475],"(29%),":[476],"(21%),":[479],"anemia,":[481,498],"vomiting,":[482],"fatigue":[483],"(9%":[484],"each).":[485],"Of":[486,589],"these":[487,560],"related":[488],"there":[493],"creatinine,":[503],"fatigue.":[508],"no":[511],"AEs.":[514],"Efficacy":[515],"Among":[516],"10":[520],"who":[523],"only":[524],"achieved":[529,595],"improvement.":[532],"Analyzing":[533],"levels,":[536],"palpable":[538],"spleen":[539],"length":[540],"\u226550%":[543,580],"seen":[545],"15":[547],"27":[549],"evaluable":[550],"(56%)":[552],"any":[554],"time.":[555],"median":[557],"duration":[558],"responses":[561],"18.3":[563],"(range":[565],"0.7":[567],"148.1":[569],"weeks).":[570],"12":[572],"weeks,":[573],"56%":[574],"(15/27)":[577],"improvement":[581],"Total":[583],"Score":[585],"MPN-SAF.":[588],"patients,":[593],"clinicohematologic":[597],"PR.":[598],"Findings":[599],"central":[602],"pathology":[603],"review":[604],"serial":[606],"bone":[607],"samples":[609],"will":[610],"presented":[612],"meeting.":[615],"Conclusions":[616],"A":[617],"phase":[619],"II":[620,646],"dosing":[624],"identified":[628],"as":[629],"has":[634],"been":[635],"well":[636],"improvements,":[642],"supporting":[643],"ongoing":[644],"MPNs.":[651],"Disclosures:":[652],"Verstovsek:":[653],"Eli":[654],"Lilly":[655,661,686,692,697,703,708,713,718],"Co:":[657,663,688,694,699,705,710,715,720],"Research":[658,664,667,670,673,676,680,683,689,721],"Funding.":[659,684,690,722],"Mesa:Eli":[660],"Funding;":[665,668,671,674,677,681],"Genetech:":[666],"Gilead:":[669],"Incyte:":[672],"Sanofi:":[675],"NS":[678],"pharma:":[679],"Celgene:":[682],"Salama:Eli":[685],"Giles:Eli":[691],"Employment.":[695,700,706,711,716],"Pitou:Eli":[696],"Hayden":[701],"Zimmermann:Eli":[702],"Price:Eli":[707],"Walgreen:Eli":[712],"Prchal:Eli":[717]},"counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":9},{"year":2014,"cited_by_count":9}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}